Keyword: Roivant Sciences
Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.
A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.
Arbutus Biopharma is dumping one of its Roivant-backed programs after two healthy people in a phase 1 study developed acute hepatitis.
HSAC will buy the Roivant business but the resulting company will take Immunovant’s name, management team and strategic focus.
The deal could provide Dainippon with a series of new products to offset the upcoming loss of patent protection on bipolar depression drug Latuda.
Axovant raised the biggest biotech IPO of 2015 but crashed and burned a few years later. Time will tell if a 2018 pivot to gene therapy will be the company's saving grace.
Zeldin, who last worked as CMO of Acceleron Pharma, arrives at Immunovant shortly after it moved its lead drug into phase 2 trials in two indications.
The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.
Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.
Another day, another biopharma veteran hits the exit and walks straight into the arms of Vivek Ramaswamy.